4,901 trials
Hyperlipidemia
Primary: Number of Participants With Adverse Events — 7; 2; 5; 4 participants
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
Multiple Sclerosis
Primary: Maximum Plasma Concentration (Cmax) of Cladribine — 20.7; 20.3 nanogram/milliliter
Pancreatic Cancer
Primary: Maximum Tolerated Dose (MTD) — 36; 750; 625 mg/m^2
Head and Neck Cancer · Liver Cancer · Breast Cancer
Primary: Number of Participants With Adverse Events — 23; 23 participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Percentage of participants
Hepatic Insufficiency
Primary: Maximum Observed Plasma Concentration (Cmax) of BMS-790052 — 380; 382; 317; 698 nanograms/milliliter (ng/mL)
Unspecified Adult Solid Tumor, Protocol Specific
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: Occurrence of Dose Limiting Toxicities (DLT) — 3; 2; 4; 3 Participants
Schizophrenia
Primary: Change in Cognition — 0.7 Change in BACS Composite Score
Malignant Melanoma
Primary: Geometric Mean Ratio of Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Observed Sampling Time (AUC[0-last]) of Probe Parent Drugs — 2.56…
Hypersensitivity · Anaphylaxis
Primary: Percentage of Participants With Adjudicated Symptoms of Hypersensitivity — 1.3; 6.6; 9.5 percentage of participants
Solid Tumor
Primary: Maximum Tolerated Dose (MTD) of the Combination of Pertuzumab and Capecitabine — 1250 mg/m^2
Healthy Volunteer, Female, Breast
Primary: Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells — 0.084; -0.100; -0.081 log ratio — p=0.2966
Healthy
Primary: AUC(0-∞) for Empagliflozin — 4330; 4110; 1680; 1630 nmol * h/L — p=0.0000